Brief: electroCore Q2 Net Income USD -3.671 Million

electroCore,.

06/08/2025 21:05

Overview

ElectroCore Inc Q2 revenue rises 20% yr/yr, beating analyst expectations

Co's GAAP net loss widens to $3.7 mln due to higher expenses

Completed acquisition of NeuroMetrix, raised $7.2 mln through term debt facility

Outlook

Company expects 2025 revenue to be approximately $30 mln

Company projects net cash usage of $3.9 mln to $4.4 mln for 2025

Company plans increased R&D expenses for remainder of 2025

Result Drivers

VA MARKET GROWTH - Return to normalized growth in the Veterans Administration market drove record Q2 revenue

PRODUCT SALES - Higher sales of prescription products to the U.S. Department of Veterans Affairs and growth in nonprescription wellness products, Truvaga™ and TAC-STIM, contributed to the 20% revenue increase

NEUROMETRIX ACQUISITION - Completion of NeuroMetrix, Inc. acquisition ahead of schedule noted as a significant achievement by CEO Dan Goldberger

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$7.38 mln
$7.22 mln (3 Analysts)
Q2 Net Income
-$3.67 mln
Q2 Operating Income
Miss
-$3.51 mln
-$2.53 mln (3 Analysts)
Q2 Pretax Profit
Miss
-$3.67 mln
-$2.51 mln (3 Analysts)
Q2 Gross Profit
$6.44 mln
Q2 Operating Expenses
$9.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for electroCore, Inc. is $22.40, about 69.4% above its August 5 closing price of $6.86

Press Release: ID:nGNX8m1FMn

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)